Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2017
Quality over quantity more important in health outcomes
2 February 2017 - When it comes to making a difference in people’s lives, it’s not about how many medicines ...
Posted by Michael Wonder on 20 Dec 2016
Proposal to maintain full subsidy for gefitinib (Iressa) from 1 April 2017
20 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of funding for gefitinib ...
Posted by Michael Wonder on 23 Oct 2016
Woman battling rare cancer gets PHARMAC funding for drug
24 October 2016 - A young woman with a body riddled with fast growing tumours, who was left in a ...
Posted by Michael Wonder on 20 Oct 2016
Woman in limbo over rare cancer treatment
21 October 2016 - For 23-year-old Olivia Fryer, three weeks could be everything. ...
Posted by Michael Wonder on 31 Aug 2016
Q&A: Is NZ lagging in cancer drug funding?
31 August 2016 - Researchers have called for an urgent overhaul of New Zealand's processes for funding cancer drugs to ensure ...
Posted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 28 Aug 2016
Cancer campaigner and melanoma patient Jeffrey Paterson dies aged 23
28 August 2016 - Young melanoma patient Jeffrey Paterson helped to win the campaign for Government funding of Keytruda, but didn't ...
Posted by Michael Wonder on 21 Aug 2016
The impact of innovative pharmaceuticals on New Zealand cancer patients
22 August 2016 - Medicines New Zealand is hosting an educational seminar in Wellington on Wednesday 24 August with University of ...
Posted by Michael Wonder on 21 Aug 2016
Economist visits New Zealand to present ground-breaking cancer research
22 August 2016 - Renowned American economist, Professor Frank Lichtenberg, has been commissioned by Medicines New Zealand to analyse the impact ...
Posted by Michael Wonder on 18 Aug 2016
Subsidised access to new melanoma drugs: in need of further innovation?
19 August 2016 - New Zealand is now the melanoma capital of the world but is behind the rest of ...
Posted by Michael Wonder on 17 Aug 2016
Reform PHARMAC or people will die, melanoma survivor tells MPs
17 August 2016 - Leisa Renwick planned to spend Mother's Day last year with her family but ended up in Tauranga ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...
Posted by Michael Wonder on 30 Jun 2016
New Zealand Pharmaceutical Schedule - 1 July 2016 update
1 July 2016 - The beginning of a new financial year sees the listing of some new medicines. ...
Posted by Michael Wonder on 30 Jun 2016
PHARMAC's credibility questioned by Labour
29 June 2016 - The acceptance of Keytruda's effectiveness after PHARMAC's budget was boosted undermines the medicines funding agency's credibility, Labour ...
Posted by Michael Wonder on 29 Jun 2016
Consultation open on pembrolizumab funding
29 June 2016 - PHARMAC has commenced consultation on a proposal to fund pembrolizumab (Keytruda) from 1 September 2016. If funded, ...